Figure 3 | Signal Transduction and Targeted Therapy

Figure 3

From: A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity

Figure 3

Therapeutic animal experiments in vivo. (a) The protocol of therapeutic immunotherapy. (b) 6-week-old Balb/c challenged with CT26 tumor (n=8), were immunized with vaccines expressing PD-1 antibody and GM-CSF cytokine as the protocol in (a) Tumor growth curve of C26 therapeutic animal model is also shown. Data are representative of three experiments. (c) 6-week-old C57BL/6 mice challenged with B16-F10 tumor (n=8), were immunized with vaccines expressing PD-1 antibody and GM-CSF cytokine as the schedule in (a) Tumor growth curve of B16-F10 therapeutic animal model is also shown. Data are representative of three experiments. (n=8). (d) Overall survival. Mice (n=8) were injected s.c. (subcutaneously) with 1×106 CT26 tumor cells on day 0 and subsequently vaccinated and treated with vaccines as indicated in (c). Survival curve as shown and results are representative of three independent experiments. (e) Overall survival. Mice (n=8) were injected s.c with 1×106 B16-F10 tumor cells on day 0 and subsequently vaccinated and treated with vaccines as indicated in (d). Survival curve as shown and results are representative of three independent experiments.

Back to article page